A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
暂无分享,去创建一个
F. Souza-Fonseca-Guimaraes | G. McArthur | J. Oliaro | C. Cullinane | R. Young | K. Sheppard | N. Haynes | Laura Kirby | Emily J. Lelliott | P. Lau | A. Slater | S. Abuhammad | K. Ramsbottom | Rachael Walker | Jessica Michie | Katrina M. Meeth | Claire A. Martin | R. J. Young
[1] Christopher A. Lazarski,et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy , 2018, Cell Research.
[2] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[3] K. Blenman,et al. UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model , 2017, Pigment cell & melanoma research.
[4] S. Carter,et al. Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma , 2017, Immunity.
[5] Jos Jonkers,et al. Genetically engineered mouse models in oncology research and cancer medicine , 2016, EMBO molecular medicine.
[6] J. Lunceford,et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Graeber,et al. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells , 2016, Cancer Immunology Research.
[8] M. Bosenberg,et al. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations , 2016, Pigment cell & melanoma research.
[9] H. Kohrt,et al. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] T. Schumacher,et al. Neoantigen landscape dynamics during human melanoma–T cell interactions , 2016, Nature.
[11] J. Wargo,et al. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy , 2016, Current Oncology Reports.
[12] J. Wolchok,et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.
[13] L. Ferrucci,et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance , 2016, Nature.
[14] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[15] Audrey Andrews. Treating with Checkpoint Inhibitors-Figure $1 Million per Patient. , 2015, American health & drug benefits.
[16] R. Rosell,et al. Melanoma: oncogenic drivers and the immune system. , 2015, Annals of translational medicine.
[17] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[18] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[19] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[20] C. Meyer,et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.
[21] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[22] Michael R Stratton,et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.
[23] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[24] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[25] N. Rosen,et al. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. , 2014, Cancer cell.
[26] Y. Kluger,et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response , 2014, Oncogene.
[27] S. Rosenberg,et al. Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.
[28] Alexander M. Menzies,et al. Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma , 2014, Clinical Cancer Research.
[29] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[31] A. Ribas,et al. Targeting oncogenic drivers and the immune system in melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[33] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[34] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[35] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[36] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[37] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[38] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[39] B. Kavanagh,et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. , 2008, Blood.
[40] J. Bluestone,et al. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.
[41] E. Vadai,et al. Exuberated numbers of tumor-specific T cells result in tumor escape. , 2008, Cancer research.
[42] Kevin M Brindle,et al. Monitoring T‐lymphocyte trafficking in tumors undergoing immune rejection , 2005, Magnetic resonance in medicine.
[43] D. Brown,et al. Tumours can act as adjuvants for humoral immunity , 2001, Immunology.
[44] J. Wolchok,et al. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma , 2018, JAMA oncology.
[45] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.